FDA Approval: Repotrectinib, a ROS1 and NTRK inhibitor

episode

Lung Cancer Considered not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

recent transcribed audio

Finance and Budget Committee - Sep 15, 2026 1h 43m · 15 Sep 2026 · Prince William County Finance and Budget Committee

The Art of True Happiness | Dr. Arthur Brooks 2h 49m · 14 Sep 2026 · Huberman Lab

The Chris Wolfe Podcast: The Power of Quality Supplements 48 min · 14 Sep 2026 · EyeCode Media

NPR News: 09-13-2026 6PM EDT 4 min · 13 Sep 2026 · NPR News Now

Guenther Steiner's 2026 Madrid GP Recap! | Vankah Hours S3E18 1h 11m · 13 Sep 2026 · The Red Flags Podcast

1208: TM Europe win the '26 Solheim Cup 1h 49m · 13 Sep 2026 · No Laying Up - Golf Podcast

Report any issue

Source

Recorded30 Nov 2023

Publisherfeeds.soundcloud.com ↗

Handlerec:2151569

Show notes

Lung Cancer Considered host Dr. Stephen Liu moderates a discussion on the November 15, 2023, US FDA approval of repotrectinib for advanced NSCLC with a ROS1 gene fusion based on the single-arm, multi-cohort TRIDENT-1 trial.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related